Study wrapper · #883
Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.
Editor's note
A well-powered meta-analysis of 22 randomized trials reporting an association between tirzepatide and reduced major adverse cardiovascular events (OR 0.87) and lower all-cause mortality, rated high certainty with low risk of bias. The composite benefit did not carry through to individual MACE components or heart failure hospitalizations, so the signal rests on the pooled endpoint. This is among the strongest evidence tiers we cover and is squarely about a tracked peptide.
Plain-language abstract
A meta-analysis of 22 randomized trials with over 29,000 participants found tirzepatide was associated with a lower rate of major adverse cardiovascular events and lower all-cause mortality in people with type 2 diabetes or overweight/obesity. A dose-response pattern was observed, though individual cardiovascular components did not reach significance.